
India Proposes Separate Licences for Bulk Drug Sellers under NDPS Oversight
Illustration: NexVani Media
The Ministry of Health and Family Welfare has proposed a dedicated licensing system for the wholesale of bulk drugs to strengthen pharmaceutical supply chain accountability.
The Union government has moved to overhaul pharmaceutical supply chains by introducing a dedicated licensing framework for the wholesale trade of bulk substances. Under amendments drafted for the Drugs Rules of 1945, the Ministry of Health and Family Welfare aims to establish separate application and licence forms, specifically designated as 19-BC and 20-BC, for active and inactive bulk drugs. Presently, a single common licence covers both final formulations and raw bulk products, but the upcoming changes will separate these categories to ensure targeted monitoring.
Officials stated that the new regulations will explicitly capture wholesale activities involving substances governed by the india ndps act. By tracking these sensitive materials through specialized documentation, the administration seeks to improve enforcement regarding antimicrobial resistance and the movement of restricted compounds. Furthermore, the physical distribution and sale of these bulk inputs must operate under the direct supervision of a qualified, competent person to guarantee proper handling.
Dedicated wholesale licences for bulk drugs aim to strengthen supply chain accountability and regulatory oversight.
The initiative received formal agreement from the Drugs Consultative Committee during its sixty-seventh meeting in late November 2025, followed by endorsement from the Drugs Technical Advisory Board in mid-February 2026. Following these consultations, authorities opened the draft proposal for public review, inviting written suggestions and objections from interested stakeholders within a thirty-day window from the date of the official gazette publication.
To ease compliance for existing operators, current license holders will not face immediate disruptions. The revised mandates will apply only after their existing retention period expires or exactly twelve months following the official final publication of the new rules, whichever timeframe proves to be later.
Why it matters
The proposed regulatory shift transforms how raw pharmaceutical components move through national distribution networks. By separating bulk substances from finished medicines, authorities gain enhanced administrative control over sensitive inventories, directly impacting pharmaceutical manufacturers, wholesale distributors, and regulatory enforcement bodies across the country.
Sources
More like this

UK Vulnerable to Covid Due to Border and Test Failures

Meta Removes Anti-Vaccine Posts Following Report on CHD

NSW mother ignored medical advice for twin home birth, inquest hears

